Latest news
KRYS: 2Q 2026 delivered record revenue and EPS, driven by global VYJUVEK growth and pipeline progress - TradingViewTradingView · Mon, 03 Aug 2026 19:36:15 GMTKRYS: Q2 2026 delivered 24% revenue growth, strong VYJUVEK demand, and advancing clinical milestones - TradingViewTradingView · Mon, 03 Aug 2026 14:46:23 GMTKRYS: Strong Q2 revenue, robust U.S. growth, and advancing pipeline position the company for continued success - TradingViewTradingView · Mon, 03 Aug 2026 13:52:49 GMTKRYS: Q2 2026 revenue rose 24% to $119.2M, with 95% gross margin and 43% net income growth - TradingViewTradingView · Mon, 03 Aug 2026 11:06:29 GMTKRYS: Q2 2026 delivered strong revenue growth, high margins, and advancing global expansion - TradingViewTradingView · Mon, 03 Aug 2026 11:02:39 GMTKRYS Q2'26 Earnings: EPS estimate is 1.73 USD - TradingViewTradingView · Fri, 31 Jul 2026 07:00:00 GMTWeekly Recap: S&P MidCap 400 inclusion and Q2 2026 results Aug 3 - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT